EdwinDeJesusMDFACP, FIDSA
Infectious Disease • Orlando, FLHIV/AIDS Medicine, STD Medicine
Medical Director - Orlando Immunology Center and Assistant Professor - UCF College of Medicine
Dr. DeJesus is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
1707 North Mills Avenue
Orlando, FL 32803Phone+1 407-647-3960Fax+1 407-413-5775- Is this information wrong?
Education & Training
Drexel University College of Medicine/Hahnemann University HospitalFellowship, Infectious Disease, 1991 - 1993- Drexel University College of Medicine/Hahnemann University HospitalResidency, Internal Medicine, 1988 - 1991
University of Puerto Rico School of MedicineClass of 1988
Certifications & Licensure
FL State Medical License 1993 - 2026
PA State Medical License 1990 - 1994
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification Centricity Practice Solution EMR, GE Healthcare, 2014
Clinical Trials
- Study of Once Daily Elvucitabine Versus Lamivudine in Participants With a Documented M184V Mutation Start of enrollment: 2006 Mar 31
- Evolution of L74V or K65R Mutations in VIremic Subjects on Tenofovir Disoproxil Fumarate (TDF) or Abacavir (ABC) (EVITA) Start of enrollment: 2006 Apr 01
- Open-Label, 48-Week Extension Study of Elvucitabine in Combination With Background Antiretroviral Therapy (ART) for Participants Who Have Completed Study ACH443-014A Start of enrollment: 2006 Sep 01
- Join now to see all
Publications & Presentations
PubMed
- 6 citationsWeek 96 Genotypic and Phenotypic Results of the Fostemsavir Phase 3 BRIGHTE Study in Heavily Treatment-Experienced Adults Living with Multidrug-Resistant HIV-1.Margaret Gartland, Pedro Cahn, Edwin DeJesus, Ricardo Sobhie Diaz, Robert Grossberg, Michael Kozal, Princy Kumar, Jean-Michel Molina, Fernando Mendo Urbina, Marcia Wan...> ;Antimicrobial Agents and Chemotherapy. 2022 Jun 21
- 40 citationsSafety and antiviral activity of triple combination broadly neutralizing monoclonal antibody therapy against HIV-1: a phase 1 clinical trial.Boris Julg, Kathryn E Stephenson, Kshitij Wagh, Sabrina C Tan, Rebecca Zash, Stephen Walsh, Jessica Ansel, Diane Kanjilal, Joseph Nkolola, Victoria E K Walker-Sperling...> ;Nature Medicine. 2022 Jun 1
- 53 citationsCapsid Inhibition with Lenacapavir in Multidrug-Resistant HIV-1 Infection.Sorana Segal-Maurer, Edwin DeJesus, Hans-Jurgen Stellbrink, Antonella Castagna, Gary J Richmond, Gary I Sinclair, Krittaecho Siripassorn, Peter J Ruane, Mezgebe Berhe,...> ;The New England Journal of Medicine. 2022 May 12
- Join now to see all
Journal Articles
- Fostemsavir in Adults with Multidrug-Resistant HIV-1 InfectionMichael Kozal, Edwin Dejesus, Cyril Llamoso, The New England Journal of Medicine
Press Mentions
Treatment-Related Early Discontinuations and Adverse Events Among Newly Diagnosed People Living with HIV Initiating Integrase Inhibitors in a Real-World SettingFebruary 1st, 2023- Orlando Trial for New Types of COVID-19 Monoclonal Antibody Treatment Seeks ParticipantsDecember 15th, 2021
- 'Elite Neutralizing' Antibody Demonstrates Long-Term Viral Suppression in Persons Living with HIV in Phase 1 TrialOctober 14th, 2021
- Join now to see all
Hospital Affiliations
Orlando Health Orlando Regional Medical CenterOrlando, Florida
AdventHealth OrlandoOrlando, Florida
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
